Although prion infections are likely to be acquired orally, animal studies have shown that peripheral infection with prions may occur by a variety of routes (17) . These studies have shown that following peripheral inoculation, most prion strains accumulate in the lymphoreticular system. The site for accumulation of prion infectivity and the disease-associated protein, designated PrP Sc , during the lymphoreticular phase is the follicular dendritic cell (FDC) network within germinal centers of lymphoid tissue (16, 19) . Following accumulation within lymphoid tissue, prions migrate along peripheral nerves to the brain, presumably via the spinal cord (7, 10, 11) or the vagus nerve (2) .
The function of FDCs in peripheral prion pathogenesis is regulated in part by B cells, which provide growth and differentiation factors for the stroma-derived cells (1, 6) . B cells can be divided into two phenotypically and functionally distinct populations, referred to as B-1 cells (Ly-1) and conventional B cells (B-2) (8, 13) . B-1 cells are in a more activated state than B-2 cells (28) and are a major source of antibody production (29) .
Signal transduction through a B-cell receptor primarily determines the fate and function of B cells and is regulated by other cell surface receptors such as the CD19/CD21 complex, which serves as a positive regulator for an immune response (21) . In contrast, negative regulators such as CD22 are crucial for terminating B-cell-receptor signal transduction to avoid improper immune response against self-antigens (21). These coreceptor-mediated B-cell immune regulatory functions may also extend to an effect upon the FDC network. To test this hypothesis, we investigated prion pathogenesis in mice that lacked either CD19 or CD22. Since CD19 Ϫ/Ϫ mice (24) have a decreased number of B-1 cells whereas CD22 Ϫ/Ϫ mice (20) contain fewer B-2 cells, we reasoned that these experiments would also address the role of different B-cell subsets in peripheral prion pathogenesis.
Following intracerebral challenge of mice with either a low dose (3 ϫ 10 3.1 50% lethal doses [LD 50 ]) or a high dose (3 ϫ 10 6.1 LD 50 ) of RML prions, the incubation times to terminal prion disease were similar in wild-type, CD19
Ϫ/Ϫ , and CD22 Ϫ/Ϫ mice ( Fig. 1A and B) . Surprisingly, the absence of CD19 resulted in a reduced incubation time after peripheral exposure to RML prions which was independent of the injected dose. CD19 Ϫ/Ϫ mice developed terminal disease in a significantly shorter incubation time than did control mice (129Sv) after intraperitoneal (i. (Fig. 1D) . In contrast, CD22 Ϫ/Ϫ mice showed an incubation time similar to that seen with control mice (C57BL/6) after i.p. challenge with either a high dose (Fig.  1C) . Regardless of the difference in latency upon infection with a low dose, prion titers ( (26), respectively. Furthermore, the prion titers during the disease progression (at days 34 and 90) were determined by a bioassay (5) of different splenic cell fractions (B cells, T cells, non-B/T cells, and a stromal fraction) isolated by magnetically activated cell sorting as previously described (23) . Again, similar levels of prion infectivity were found in cell fractions from CD19 Ϫ/Ϫ and wild-type mice. These findings imply that the reduced incubation time in CD19 Ϫ/Ϫ mice was not the result of an increased accumulation of prions within either the spleen lymphoid cell fraction or the FDC-containing stromal fraction.
To search for alterations in the microarchitecture of the lymphoid organs responsible for the shorter incubation time of prion disease in CD19 Ϫ/Ϫ mice, spleen sections were analyzed by immunostaining. Neither the number of T cells stained with either anti-CD4 or anti-CD8 antibodies nor the distribution of B cells stained with either anti-CD45R or peanut agglutinin was altered in comparison to that in the wild-type mice (data not shown). Moreover, the numbers of FDC networks in the spleen assessed with antibodies against FDC-M1 and CD21/ CD35 appeared to be similar (data not shown), and morphometric measurements revealed similar numbers of FDC networks in spleen sections of CD19 Ϫ/Ϫ , CD22 Ϫ/Ϫ , and wild-type (129Sv) mice (Fig. 3C) .
Surprisingly, the FDC networks within the white pulp of spleens of CD19 Ϫ/Ϫ mice seem to be altered with respect to the distance between the FDC networks and innervating nerve fibers visualized by double labeling against CD21/CD35 and tyrosine hydroxylase (THL), respectively. As shown in Fig. 3A , the distance between the FDC network and the dense plexuses of nerve fibers surrounding the central arterioles in spleen sections from CD19 Ϫ/Ϫ mice was reduced compared to that seen in CD22
Ϫ/Ϫ and wild-type (129Sv) mice. However, the typical localization and organization of FDC networks and nerve fibers within the lymphoid follicles from all three lines are unaltered (Fig. 3A) . Moreover, the total amount of THL in the spleens of CD19 Ϫ/Ϫ mice seems to be no higher than that in CD22
Ϫ/Ϫ and wild-type mice, as determined by Western blotting (data not shown), excluding the possibility that the shorter latency of CD19 Ϫ/Ϫ mice to peripheral exposure is due to hyperinnervation of the lymphoid organs by sympathetic nerves, as recently shown (7, 10, 11) . In order to measure the altered distance between the FDC networks and nerve fibers in the spleens of CD19 Ϫ/Ϫ mice, a morphometric analysis was performed by measuring this distance in follicles of spleen sections from three uninfected mice of each genotype. A reduction of more than 50% in this distance was found in CD19 Ϫ/Ϫ mice, compared to CD22 Ϫ/Ϫ and wild-type mice (129Sv) (Fig. 3B) . These data suggest that the reduced incubation time of disease in CD19 Ϫ/Ϫ mice after peripheral application of prions is most likely related to the reduced distance between the FDC networks and innervating peripheral nerve fibers, which enables prions to be rapidly transported to the peripheral nervous system.
The conclusion reached in this study that closeness of the FDC network and the peripheral nervous system in CD19 Ϫ/Ϫ mice may allow a more efficient migration of prions between the two sites is supported by a recent study showing that positioning of the FDCs within the spleen affects prion neuroinvasion (22) . However, the accelerated response of these mice is observed only after peripheral challenge with a low dose of infectivity (22) , whereas CD19 Ϫ/Ϫ mice display a shorter incubation time after peripheral infection with either a high or a low dose of RML prions. This implies that additional factors may contribute to the phenotype described here. The activity of CD19 often relies on its association with molecules such as CD21 (4) and others (3) . Therefore, the loss of CD19 may disturb B-cell activation and function, which, if it exists, may be mediated through the complement system that has been shown The primary incubation time is the day postinoculation when the tissue was used for the bioassay. c The number of days to terminal prion disease is given as the mean Ϯ the standard deviation unless not all mice succumbed to the disease during the time period they were observed; in those cases, each value given is the number of days for each individual mouse. to facilitate neuroinvasion of prions (12, 15) . Since CD19 represents a costimulatory molecule of the complement systems, it is possible that compensatory mechanisms are up-regulated in the absence of CD19, thereby facilitating neuroinvasion of prions. However, prion titers in the spleens of prion-infected CD19 Ϫ/Ϫ mice were similar to those found in controls, excluding the possibility that the intrinsic capacity of the spleen to retain and replicate prions is altered in CD19 Ϫ/Ϫ mice ( Table  1) . FDCs may retain prions indirectly through interactions between C3 and CD21/CD35 or between C1q and C1q receptor, thereby bridging the gap between FDCs and peripheral nerves (16, 19) . In line with this idea, the reduced incubation time of CD19 Ϫ/Ϫ mice after peripheral challenge is the consequence of the shorter distance between FDCs and peripheral nerves and the compensatory activity of the complement system due to loss of CD19 on B cells.
Alternatively, significant effects on prion pathogenesis may be expected if aberrant signaling in mice devoid of CD19 leads to modulation of the cytokine response by B cells, as suggested by Matsushita et al. (18) . Various cytokines have been shown to have an effect on the development of prion disease (27) . Since mice devoid of CD19 developed a Th1 cytokine bias with reduced production of Th2 cytokines such as interleukin-10 (18), it is possible that the accelerated response of CD19 Ϫ/Ϫ mice to peripherally applied prions may due to the loss of anti-inflammatory cytokines, rather than a direct effect of loss of CD19 function. Indeed, certain inflammatory conditions are associated with an increase in the spread of prions within the host (14, 25) . PrP Sc deposition in these inflamed areas is associated with up-regulation of lymphotoxin and induction of FDCs (9) . However, the number of FDC networks in mice devoid of CD19 was not altered (Fig. 3C) .
The findings reported here support the notion that the distance between the FDC network and the adjacent peripheral nerves contributes to the neuroinvasion of prions. However, additional mechanisms might be involved in this process, which are still unknown in the understanding of peripheral prion pathogenesis. 
